Response to Mitoxantrone in Advanced Breast Cancer
Author Information
Author(s): C. Wright, J. Cairns, B.J. Cantwell, A.R. Cattan, A.G. Hall, A.L. Harris, C.H.W. Horne
Primary Institution: University of Newcastle upon Tyne
Hypothesis
Does the expression of c-erbB-2 protein and glutathione S-transferases correlate with the response to mitoxantrone in advanced breast cancer?
Conclusion
Patients with c-erbB-2 positive tumors showed a lower response rate and shorter survival after treatment with mitoxantrone.
Supporting Evidence
- 16 tumors (23%) were c-erbB-2 positive.
- Patients with c-erbB-2 positive tumors had a lower response rate (50% vs 58%).
- Survival from the start of treatment was significantly shorter for patients with c-erbB-2 positive tumors.
Takeaway
This study looked at how well a cancer drug worked in patients with advanced breast cancer and found that some patients might need stronger treatment if their tumors have certain markers.
Methodology
Patients were treated with mitoxantrone and their tumor markers were assessed to see how they correlated with treatment response.
Potential Biases
Potential bias in patient selection and response assessment.
Limitations
The study had a small sample size and did not account for all potential factors influencing treatment response.
Participant Demographics
Median age was 50 years, with a range from 25 to 76 years; all patients had previously failed endocrine therapy.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website